

**23-JAN-2018 6:10  
CANCER CONTROL ACCRUAL REPORT**

06:10 Tuesday, January 23, 2018 1

STUDY	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN
			REGS.	LAST Month	LAST Month	LAST Month	LAST Month	LAST Month	
S1007-Breast,Adj,N1,Endocrine+/-Chemo	1 Y 1	Recurrence Score testing	9383	550	129	0	0	0	BREAST
			9383	550	129	0	0	0	
	2 Y 2	Chemo and Endocrine Therapy	2547	192	53	1	0	0	
		3 Endocrine Therapy Alone	2536	198	52	1	0	0	
			5083	390	105	2	0	0	
S1207-Brst,Adj,Endocrine+/-Everolimus	1 Y 1	Blinded drug + Endocrine	734	201	87	44	12	5	BREAST
		2 Blinded drug + Endocrine	746	216	104	45	17	3	
			1480	417	191	89	29	8	
S1316-Compar. Effectiv. Trial for MBO	1 Y 1	Randomization Surgery	4	3	3	1	0	0	SURV
		2 Randomization Non-surgical M	5	5	4	4	0	0	
		3 Patient Choice Surgery	37	18	8	1	0	0	
		4 Patient Choice Non-surgical M	88	49	27	11	4	2	
			134	75	42	17	4	2	
S1400I-Non-Match: Nivo + Ipi vs Nivo	1 Y 1	Nivolumab + Ipilimumab	130	49	27	13	4	1	LUNG
		2 Nivolumab	126	47	18	6	1	0	
			256	96	45	19	5	1	
S1415CD-TrACER CSF Standing Order Intervention for FN	1 Y 1	Site assigned to Cohort	389	325	130	59	25	9	CCD
		2 Site randomized: Control	261	256	132	64	18	3	
		3 SiteRand Int Risk: CSF	392	372	240	127	45	14	
		4 SiteRand Int Risk: No CSF	282	275	182	77	13	2	
			1324	1228	684	327	101	28	
S1417CD-Colorectal, Cost Cohort Study	1 Y 1	Observation	164	146	87	43	15	5	CCD
			164	146	87	43	15	5	
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	1 Y 1	Tissue for PD-L1 testing	141	139	92	49	15	3	BREAST
			141	139	92	49	15	3	
	2 Y 2	Observation	62	62	40	23	4	1	
		3 MK-3475 (Pembrolizumab)	58	58	39	18	7	1	
	120	120	79	41	11	2			
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol	1 Y 0	Screening	4	4	4	4	1	0	SURV
			4	4	4	4	1	0	

**23-JAN-2018 6:10  
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R E G I S T R A T I O N	P E R I O D	A R M	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN
				REGS.	LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS	
	2	Y	1	Carvedilol	1	1	1	1	0	0
	2			No intervention	1	1	1	1	0	0
	3			Observation	1	1	1	1	0	0
					<u>3</u>	<u>3</u>	<u>3</u>	<u>3</u>	<u>0</u>	<u>0</u>
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1	Y	1	TICE BCG	22	22	17	7	2	1 GU
	2			Tokyo-172 BCG	21	21	16	8	2	1
	3			Prime + Tokyo-172 BCG	21	21	17	9	2	1
					<u>64</u>	<u>64</u>	<u>50</u>	<u>24</u>	<u>6</u>	<u>3</u>
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac	0	Y	0	Pre-Registration	442	127	62	34	6	2 PREV
					<u>442</u>	<u>127</u>	<u>62</u>	<u>34</u>	<u>6</u>	<u>2</u>
	1	Y	1	Blinded drug	50	18	8	5	1	1
	2			Blinded drug	36	6	0	0	0	0
	3			Blinded drug	35	4	0	0	0	0
	4			Blinded drug	57	28	16	9	4	0
					<u>178</u>	<u>56</u>	<u>24</u>	<u>14</u>	<u>5</u>	<u>1</u>